Bloomberg reported on Roche's success in Phase III trials with its new therapy for Type 2 diabetes. The GLP-1 analog (Taspoglutide) met its primary endpoints of reducing blood glucose levels in five trials. Analysts opined that while the Roche drug is not first in class, it may emerge as best in class with it's once weekly injection regimen.
Boehringer Ingelheim has placed a $913 million bid to acquire Japan's largest OTC drug firm - SSP Co. BI already owns a 60% stake in the company.
Posted by Bruce Lehr Feb 12, 2010